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Dear editor
We read with interest the results of the study from Chang et al1 in the International 
Journal of Nanomedicine. This article shows that curcumin (diferuloymethane), a 
phenolic compound extracted from the natural plant Curcuma longa L., exerts higher 
cytotoxicity in osteosarcoma MG-63 cells than in healthy human osteoblasts. Based on 
the dosages provided by the authors it is hypothesized that with the appropriate drug 
carriers, curcumin could be delivered to bone tumors and selectively kill osteosarcoma 
cells without harming healthy osteoblasts. This hypothesis is based in the data provided 
that claims the dose needed to exert a significant cytotoxicity on osteosarcoma cells was 
much lower than that needed to exert the same effect on healthy human osteoblasts. The 
topic of this study is of importance for both cancer and metabolic bone disease fields, 
we appreciate the methodology of the study, nevertheless we believe that the hypothesis 
formulated by the authors and their conclusion deserves further comment.
Closer examination of the data raises some concerns regarding the study as the 
results presented are not in agreement with several previous studies using MG-63 
cells and curcumin. Chang et al1 presents significant cytotoxicity after MG-63 cell 
exposure to 5 μM curcumin, increased cytotoxicity with 10 μM, and the highest level 
of cytotoxicity (less than the 12% of viability in the cultures) after 24 hours of expo-
sure to 25–100 μM. Our attention was drawn to the apparent high cytotoxicity of low 
concentrations of the polyphenol curcumin observed by the authors in the MG-63 
cell line-based experiments. Initially, these results appeared to be markedly different 
from observations made in several laboratories where concentrations of curcumin had 
lower cytotoxic effects. 
In 2008 Walters et al2 reported an IC50 for curcumin after 72 hours of exposure of   
19.1 μM, which was slightly lower than that reported in 2012 by Li et al3 of 22.77±1.70 μM   
(also after 72 hours of exposure). In this last study,3 significant cytotoxicity was also 
reported after 24 hours (similar to the methodology reported by Chang et al) only with 
dosages over 22.5 μM of curcumin. Our group have also reported significant cytotoxic-
ity after MG-63 cell exposure, but only with doses over 20 μM after 24 hours.4 More 
recently, and closer to the Chang et al hypothesis, curcumin has been encapsulated in 
liposomal nanoparticles and has reported to have an IC50 of 23.39 μM after 48 hours 
of exposure of MG-63 cells.5
In conclusion, we wish to thank the authors for bringing this apparent lower toxic-
ity of curcumin in healthy osteoblasts to our attention. However, their observations 
are not in agreement with the literature on MG-63 cells. Clearly further studies are 
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required in this area to establish the optimal physiological 
concentration at which curcumin may exert cytotoxic 
effects on osteosarcoma cells without cytotoxic sequelae 
over healthy osteoblasts. In addition it would be beneficial 
to compare the effects of curcumin on osteosarcoma cell 
viability across a number of different cell lines.
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Dear editor
We thank Moran et al for their interest and comments on our 
manuscript “Short communication: selective cytotoxicity 
of curcumin on osteosarcoma cells compared to healthy 
osteoblasts” recently published in the International Journal 
of Nanomedicine.1 The main point of their letter to the Editor 
concerns the different cytotoxicity values we have reported 
for curcumin on osteosarcoma cells (MG-63) compared to 
other studies. We would like to emphasize that it is very 
difficult to compare toxicity studies from one group to the 
next due to the variations in experimental protocols followed. 
We have observed many variations between our experiments 
and those experiments cited in the literature by Moran et al. 
For example, we note that for our study we used the recom-
mended cell culture medium for MG-63 cells as indicated 
by the vendor (ATCC): Eagle’s Minimal Essential Medium 
(EMEM) supplemented with 10% fetal bovine serum. In the 
studies conducted by Walters et al2 and Li et al3 Dulbecco’s 
Modified Eagle’s Medium (DMEM) (not EMEM) was used. 
While this may seem to be a minor point, we would like to 
point out that there are differences in amino acid composition 
between EMEM and DMEM that can influence MG-63 cell 
functions. Specifically, EMEM has more amino acids 
including L-Alanine, L-Asparagin H2O, and L-Asparatic 
Acid. Another major difference between the studies indi-
cated by Moran et al is the manner in which cellular toxicity 
was determined. In the articles referenced, they expressed 
MG-63 cell viability by the ratio of optical density of the 
samples to controls, but this method may not be as precise 
as the method we followed (converting the optical density 
to actual cell density by a standard curve) since a few cells 
could produce moderate optical density. We believe that 
reporting specific cell densities is a more precise manner 
to report cellular toxicities. Nonetheless, we feel the value 
in these studies, although remaining difficult to compare 
specific curcumin concentration results between them, lies 
in the general trends observed. For example, in our study, 
that a different concentration of curcumin can be used to kill 
osteosarcoma cells than noncancerous osteoblasts. Of course, 
when translating these results in vivo, we are sure that differ-
ent toxic concentrations of curcumin will also be observed 
which needs careful attention for eventual clinical use.
Disclosure
The authors report no conflicts of interest in this 
communication.
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